middle.news
Telix’s ProstACT Phase 3 Part 1 Confirms Safety, Paving Way for Global Expansion
8:34am on Tuesday 10th of March, 2026 AEDT
•
Healthcare
Read Story
Telix’s ProstACT Phase 3 Part 1 Confirms Safety, Paving Way for Global Expansion
8:34am on Tuesday 10th of March, 2026 AEDT
Key Points
Part 1 of ProstACT Phase 3 met primary safety and dosimetry goals
TLX591-Tx showed acceptable tolerability combined with standard prostate cancer therapies
No new safety signals or drug interactions observed across three patient cohorts
Part 2 trial underway in multiple countries with regulatory approvals secured
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TELIX PHARMACEUTICALS (ASX:TLX)
OPEN ARTICLE